Biologics

From company acquisitions to FDA nods, here are six key updates in orthobiologics since Oct. 4.

Acuitive Technologies earned FDA clearance for the Citrepore bioactive bone filler, the company said Nov. 12.

Biologics company Theradaptive's lead therapeutic, OsteoAdapt SP, has been featured in a preclinical spinal fusion study published in Spine, a prominent, peer-reviewed publication for spinal surgeons.

Spine biologics holds incredible potential if it can overcome obstacles related to disc anatomy, Ezriel Kornel, MD, said. 

CytexOrtho has earned FDA approval to begin a clinical trial evaluating the safety and efficacy of its absorbable hip implant in human patients, according to an Oct. 29 report from Mass Device.

Washington, D.C.-based Regenerative Orthopedics & Sports Medicine has partnered with the Orthobiologics Research Initiative to support nonsurgical orthopedic research aimed at treating partial-thickness rotator cuff tears using cutting-edge orthobiologic procedures.

Phoenix-based Full Circle Orthopedics is expanding its regenerative medicine program, according to an Oct. 22 news release. 

Since the start of 2023, several practices and health systems have added the Bridge-Enhanced ACL restoration procedure, which uses a patient's blood to help heal the injury.

Bone Biologics appointed Phillip Meikle to its board of directors, according to an Oct. 21 news release.

A woman is suing Elutia, formerly Aziyo Biologics, after contracting tuberculosis from a product used in an April 2021 spine surgery, The Atlanta Journal-Constitution reported Oct. 17.